![Frank Harder](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Frank Harder
Geen lopende functies
Profiel
Frank Harder formerly worked at Bioporto A, as Chief Financial Officer & IR Contact from 2007 to 2014, Zymenex A, as Chief Financial Officer, and PhaseOneTrials A, as Chief Financial Officer.
Mr. Harder received his graduate degree from the University of Copenhagen.
Eerdere bekende functies van Frank Harder
Bedrijven | Functie | Einde |
---|---|---|
BIOPORTO A/S | Financieel Directeur/CFO | 01-01-2014 |
Zymenex A/S
![]() Zymenex A/S BiotechnologyHealth Technology Zymenex A/S researches and develops therapeutics for life threatening diseases. The firm commercializes novel enzyme replacement therapies for the treatment of life-threatening, rare genetic diseases. The company was founded by Jens Fogh and Pär Gellerfors in 1998 and is headquartered in Hillerod, Denmark. | Financieel Directeur/CFO | - |
PhaseOneTrials A/S
![]() PhaseOneTrials A/S Miscellaneous Commercial ServicesCommercial Services PhaseOneTrials A/S is a Danish Contract Research Organization (CRO) that conducts clinical phase I trials and early phase II trials of new drug candidates. Phase I trials include studies in which a new drug is tested for the first time in healthy humans – also known as “First-in-Man” studies. Early phase II studies, or “Proof-of-Concept” studies, include testing a drug in small groups of patients to determine whether the drug has the desired effects on a given disease. | Financieel Directeur/CFO | - |
Opleiding van Frank Harder
University of Copenhagen | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
BIOPORTO A/S | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Zymenex A/S
![]() Zymenex A/S BiotechnologyHealth Technology Zymenex A/S researches and develops therapeutics for life threatening diseases. The firm commercializes novel enzyme replacement therapies for the treatment of life-threatening, rare genetic diseases. The company was founded by Jens Fogh and Pär Gellerfors in 1998 and is headquartered in Hillerod, Denmark. | Health Technology |
PhaseOneTrials A/S
![]() PhaseOneTrials A/S Miscellaneous Commercial ServicesCommercial Services PhaseOneTrials A/S is a Danish Contract Research Organization (CRO) that conducts clinical phase I trials and early phase II trials of new drug candidates. Phase I trials include studies in which a new drug is tested for the first time in healthy humans – also known as “First-in-Man” studies. Early phase II studies, or “Proof-of-Concept” studies, include testing a drug in small groups of patients to determine whether the drug has the desired effects on a given disease. | Commercial Services |